Core Viewpoint - The article highlights significant developments in the lithium battery industry, including major supply agreements, production expansions, and market price trends for key materials [3][4][5][6]. Group 1: Major Supply Agreements - LG Energy Solution has signed a six-year supply agreement with Chery Automobile for 8 GWh of 46-series cylindrical batteries, marking the first such contract between a Korean battery manufacturer and a Chinese automaker [3]. - Farasis Energy has begun supplying its 4680 cylindrical batteries to BMW for its global electric vehicle platform, with plans for increased production capacity at its facilities [4]. Group 2: Production and Investment Developments - Ruipai New Energy is nearing the completion of a project to produce 50,000 tons of lithium iron phosphate cathode materials, with the first production line expected to start by the end of June [5]. - Foshan Fospower Technology Group is acquiring Hebei Jinli New Energy Technology, with a total transaction value of 5.08 billion yuan [6]. Group 3: Lithium Material Market Conditions - The domestic lithium carbonate market price is hovering around 60,000 yuan per ton, with expectations of slight downward adjustments due to increased production and inventory digestion by downstream manufacturers [8][9]. - The price of ternary materials remains stable but may face reductions in July if new orders do not materialize [9][10]. - Phosphate lithium prices are stable, with significant production increases expected from companies like Fulin Precision Engineering [10][11]. Group 4: Battery and Electric Vehicle Market Trends - In June, domestic battery manufacturers are maintaining good production levels, with expectations for a slight decline in overall operating rates if no new projects arise [16]. - The sales of passenger vehicles reached 450,000 units, with new energy vehicle sales at 245,000 units, reflecting a year-on-year increase of 37.88% [18]. - Recent policy discussions in Hunan regarding energy storage pricing indicate a potential decline in competitive pricing for new projects [19].

特别提示： 1、根据《中华人民共和国公司法》（以下简称"公司法"）、《深圳证券 交易所上市公司自律监管指引第 9 号—回购股份》等相关规定，湖北省宏源药业 科技股份有限公司(以下简称"公司"或"本公司"）回购专用证券账户中的股 份 3,200,000 股不参与本次权益分派。本次权益分派将以公司现有总股本 400,006,800 股剔除回购专用证券账户中的股份 3,200,000 股后的股本 396,806,800 股为基数，向全体股东每 10 股派 0.30 元人民币现金（含税），实 际派发现金分红总额=396,806,800股×0.30元/10股=11,904,204.00元人民币。 证券代码：301246 证券简称：宏源药业 公告编号：2025-029 湖北省宏源药业科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 股为基数，向全体股东每 10 股派发现金股利 0.30 元人民币（含税），预计派发 现金股利人民币不超过 11,904,204 元（含税）。本次利润分配不以公积金转增 股本，不送红股，剩余未分配 ...

Financial Performance - The company's revenue and net profit are expected to show growth in Q2 2025 compared to Q1 2025, with current order volumes meeting expectations [1] - Direct exports to the U.S. account for a low percentage of revenue, minimizing the impact of recent U.S. tariffs [1] - The company has faced a significant decline in net profit since its IPO, with the stock price currently less than one-third of the initial offering price of 50 CNY per share [2][3] Market Challenges - The stock price has been in a long-term decline, attributed to macroeconomic factors, market conditions, and industry developments [2][3] - The company’s internal value does not align with its market capitalization, facing issues such as insufficient information disclosure and a lack of recognized business logic [3] Product Development - The solid-state battery project has completed kilogram-level experiments and is currently in the process optimization phase, with no mass production yet [2][4] - The company is focusing on high-end raw materials and specialty intermediates in the pharmaceutical sector, aiming to expand its international market presence [4] Strategic Initiatives - The company plans to enhance its core competitiveness through improved main business operations and effective value communication to investors [2][3] - In the lithium battery materials sector, the company aims to reduce production costs through technological upgrades and expansion into upstream supply chains [4]

湖北省宏源药业科技股份有限公司 关于参加湖北辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，湖北省宏源药业科技股份有限公司（以下 简称"公司"）将参加由湖北证监局、湖北省上市公司协会与深圳市全景网络有 限公司联合举办的"2025 年湖北辖区上市公司投资者集体接待日活动"，现将相 关事项公告如下： 证券代码：301246 证券简称：宏源药业 公告编号：2025-028 特此公告！ 湖北省宏源药业科技股份有限公司董事会 2025 年 6 月 6 日 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2025 年 6 月 12 日（星期四）14:00-16:40。届 时公司副董事长尹聃先生、财务负责人曾科峰先生、总监兼董事会秘书肖拥华先 生将在线就公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行 沟通与交流，欢迎广大投资者踊跃参 ...

Core Viewpoint - The demand for glycolic acid in China is steadily increasing, projected to rise from 98,000 tons in 2022 to 108,000 tons in 2024, driven by its applications in pharmaceuticals, fragrances, and food additives, as well as emerging sectors like lithium battery electrolytes and biodegradable plastics [1][12]. Industry Overview - Glycolic acid is an organic compound with the formula C2H2O3, characterized by its white crystalline form and various industrial applications [2]. - The market for glycolic acid is expanding due to rising living standards and increased demand in various sectors [1][12]. Production Methods - The primary production methods for glycolic acid include oxalic acid electrolysis, glyoxal nitric oxidation, and ozone oxidation of anhydride, with domestic producers predominantly using glyoxal nitric oxidation [3][4]. Industry Chain - The glycolic acid industry chain involves upstream sectors like petrochemicals and biomass energy, providing essential raw materials, while downstream applications span pharmaceuticals, pesticides, dyes, and food additives [8]. Market Competition - The Chinese glycolic acid market is characterized by a dominance of large enterprises, with significant players including Hubei Hongyuan Pharmaceutical and Qingdao Guolin Technology, while smaller firms focus on niche markets [16][17]. Industry Development Trends - Innovations in production processes, such as using biomass-derived acetyl acid, are expected to enhance efficiency and product quality [21]. - Increased international cooperation is anticipated, particularly under the Belt and Road Initiative, which may expand market share and enhance technological capabilities [22]. - The pharmaceutical sector's growth is likely to broaden the consumption of glycolic acid, solidifying its market position as a crucial raw material for various drugs [24].

证券代码：301246 证券简称：宏源药业 公告编号：2025-027 湖北省宏源药业科技股份有限公司 湖北省宏源药业科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第四届董事会第十次会议，审议通过了《关于开立募集资金专用账户的议 案》，同意：1、新开立新募集资金账户，将公司在浙商银行股份有限公司武汉 分行营业部开立的募集资金账户（账号：5210000010120100458761）中的募集资 金全部转移至新募集资金账户中，用于"年产 25 亿片（粒）高端制剂车间项目" 资金的使用和管理；2、将公司在浙商银行股份有限公司武汉分行营业部开立的 超募资金账户（账号：5210000010120100460417）中的超募资金余额转至已开立 的超募资金账户。同时授权公司财务部具体办理募集资金专项账户开设及募集资 金监管协议签署等事宜，相关事项办理完毕后原募集资金账户将注销。 近日，公司与中信银行股份有限公司武汉分行、保荐机构民生证券股份有限 公司签订了募集资金三方监管协议，同时将原部分募集资金账户进行注销，具体 情况公告如下： 一、募集资金的情况概述 经中国证券监督管理委员会《关于同意湖北省 ...

Market Overview - The Shanghai Composite Index is at 3381.72 points, above the six-month moving average, with a slight increase of 0.05% [1] - The total trading volume of A-shares today is 478.92 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 167 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Foshan Plastics Technology (5.68%) - Hongyuan Pharmaceutical (4.75%) - Jingzhida (4.32%) [1] Stock Performance Details - The following stocks have notable performance metrics: - Foshan Plastics Technology: Today's increase of 6.64%, turnover rate of 6.58%, six-month average price of 6.54 yuan, latest price at 6.91 yuan [1] - Hongyuan Pharmaceutical: Today's increase of 5.30%, turnover rate of 5.76%, six-month average price of 13.84 yuan, latest price at 14.50 yuan [1] - Jingzhida: Today's increase of 6.36%, turnover rate of 3.24%, six-month average price of 75.53 yuan, latest price at 78.79 yuan [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the six-month moving average include: - Zhongyi Technology: Deviation rate just above the average - Yuanli Technology: Deviation rate just above the average - Alade: Deviation rate just above the average [1]

上海市通力律师事务所 关于湖北省宏源药业科技股份有限公司 2024 年年度股东大会的法律意见书 致: 湖北省宏源药业科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受湖北省宏源药业科技股份有限公司(以 下简称"公司")的委托, 指派本所徐青律师、章唐乾律师(以下简称"本所律师")根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规 范性文件(以下统称"法律法规")及《湖北省宏源药业科技股份有限公司章程》(以下简称 "公司章程")的规定就公司 2024 年年度股东大会(以下简称"本次股东大会")相关事宜 出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有 签署、盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和有 效的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的 ...

2024 年年度股东大会决议公告 证券代码：301246 证券简称：宏源药业 公告编号：2025-026 湖北省宏源药业科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会召开期间没有增加或变更议案； 3、本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 （1）现场会议召开时间：2025 年 5 月 16 日（星期五）下午 14:30 （2）网络投票时间：2025 年 5 月 16 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 16 日上午 9:15–9:25，9:30-11:30，下午 13:00-15:00； 通过深圳证券交易所互联网投票的具体时间为：2025 年 5 月 16 日（星期五） 9:15-15:00 的任意时间。 2、现场会议召开地点：罗田县凤山镇经济开发区宏源路 6 号公司会议中心 1 号会议室 3、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式 ...

在资本市场的潮起潮落中，宏源药业的股价走势堪称一场令人揪心的"跳水表演"。从上市首日的破发窘境，到两年间股价从45元一路狂泻至13.7元，并且 跌势至今未止，宏源药业究竟经历了什么？这背后又隐藏着哪些不为人知的秘密呢？ 上市即破发，美梦碎成泡影 如果说上市首日破发只是噩梦的开始，那么接下来宏源药业的业绩表现，则彻底让股价踏上了雪崩之路。上市后，宏源药业的业绩随即变脸。2023年上半 年，公司归母净利润同比下滑78.51%，经营活动产生的现金流量净额同比下滑198.11%。全年来看，2023年归母净利润为8300万元至9700万元，同比下降 80.91%至77.69%。 业绩下滑的原因，一方面是公司所处行业竞争激烈。在锂电池材料领域，六氟磷酸锂销售价格持续在低位徘徊，虽然宏源药业六氟磷酸锂产销规模保持增 长，但产品售价同比大幅下降，导致盈利能力降低。另一方面，受国家集采和医保政策影响，医药终端竞争加剧，原料药市场竞争也愈发激烈。宏源药业 的甲硝唑产销量虽有增长，但产品单位售价下降幅度大于单位成本下降幅度，产品毛利下降，进而影响了公司整体盈利能力。 糟糕的业绩反映在股价上，便是一路阴跌不止。从上市首日盘中创下的4 ...